Financials Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-15 pm EDT 5-day change 1st Jan Change
53.34 USD -1.22% Intraday chart for Exact Sciences Corporation -10.32% -27.90%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 13,616 21,070 13,412 8,797 13,379 9,843 - -
Enterprise Value (EV) 1 14,120 20,573 14,561 10,401 14,916 11,431 11,027 10,499
P/E ratio -145 x -23.6 x -22.4 x -14 x -65.5 x -51.3 x -566 x 70.7 x
Yield - - - - - - - -
Capitalization / Revenue 15.5 x 14.1 x 7.59 x 4.22 x 5.35 x 3.48 x 3.06 x 2.72 x
EV / Revenue 16.1 x 13.8 x 8.24 x 4.99 x 5.97 x 4.04 x 3.42 x 2.9 x
EV / EBITDA -117 x 789 x -77.4 x -72.5 x 68.2 x 34.5 x 21.8 x 15.7 x
EV / FCF -49.2 x 285 x -61.2 x -23.7 x 467 x 163 x 34.5 x 20 x
FCF Yield -2.03% 0.35% -1.63% -4.21% 0.21% 0.61% 2.9% 5%
Price to Book 5.97 x 7.09 x 3.94 x 2.87 x 4.27 x 3 x 2.81 x 2.57 x
Nbr of stocks (in thousands) 147,232 159,030 172,319 177,684 180,850 184,530 - -
Reference price 2 92.48 132.5 77.83 49.51 73.98 53.34 53.34 53.34
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 876.3 1,491 1,767 2,084 2,500 2,831 3,222 3,619
EBITDA 1 -120.7 26.08 -188.1 -143.4 218.8 331.5 506.9 669.9
EBIT 1 -170.9 -137.3 -599.4 -580 -259.1 -185.9 -7.216 145.4
Operating Margin -19.51% -9.21% -33.92% -27.83% -10.36% -6.57% -0.22% 4.02%
Earnings before Tax (EBT) 1 -268.9 -857.1 -842.5 -632.6 -201.7 -183.5 -7.141 158.5
Net income 1 -83.99 -848.5 -595.6 -623.5 -204.1 -195.6 -24.28 130
Net margin -9.59% -56.9% -33.71% -29.91% -8.17% -6.91% -0.75% 3.59%
EPS 2 -0.6400 -5.610 -3.480 -3.540 -1.130 -1.040 -0.0942 0.7549
Free Cash Flow 1 -286.8 72.13 -238 -438 31.93 70.1 319.4 524.8
FCF margin -32.73% 4.84% -13.47% -21.02% 1.28% 2.48% 9.91% 14.5%
FCF Conversion (EBITDA) - 276.6% - - 14.59% 21.15% 63.01% 78.34%
FCF Conversion (Net income) - - - - - - - 403.82%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 473.8 486.6 521.6 523.1 553 602.4 622.1 628.3 646.9 637.5 692.2 731.4 771.8 733.8 790.5
EBITDA 1 -122.2 -89.82 -45.77 -13.04 4.934 45.91 66.85 56.28 49.71 39.2 70.43 102.9 121.8 80.81 121.3
EBIT 1 -222.2 -202.9 -162.1 -119.9 -95.34 -65.73 -72.1 -68.07 -70.93 -88.28 -57.51 -24.13 -8.157 -49.5 -11.38
Operating Margin -46.9% -41.71% -31.08% -22.93% -17.24% -10.91% -11.59% -10.83% -10.97% -13.85% -8.31% -3.3% -1.06% -6.75% -1.44%
Earnings before Tax (EBT) 1 -224.9 -183 -167.8 -151.9 -129.9 -72.48 -79.92 1.043 -50.38 -108.4 -56.81 -22.41 -8.553 -49.92 -10.98
Net income 1 -220.6 -180.9 -166.1 -148.8 -127.7 -74.15 -81.03 0.794 -49.77 -110.2 -58.36 -25.75 -8.29 -51.24 -14.85
Net margin -46.56% -37.19% -31.83% -28.44% -23.1% -12.31% -13.02% 0.13% -7.69% -17.29% -8.43% -3.52% -1.07% -6.98% -1.88%
EPS 2 -1.280 -1.040 -0.9400 -0.8400 -0.7200 -0.4200 -0.4500 - -0.2700 -0.6000 -0.3050 -0.1338 -0.0357 -0.2445 -0.0528
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/22/22 4/26/22 8/2/22 11/3/22 2/21/23 5/9/23 8/1/23 11/1/23 2/21/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 504 - 1,150 1,604 1,537 1,588 1,184 656
Net Cash position 1 - 497 - - - - - -
Leverage (Debt/EBITDA) -4.176 x - -6.114 x -11.19 x 7.024 x 4.791 x 2.335 x 0.979 x
Free Cash Flow 1 -287 72.1 -238 -438 31.9 70.1 319 525
ROE (net income / shareholders' equity) -5.66% -33.2% -21.2% -18.4% -9.08% -4.78% 0.26% 5.1%
ROA (Net income/ Total Assets) -3.34% -20.1% -10.3% -9.16% -4.42% -3.2% -0.45% 2.05%
Assets 1 2,515 4,215 5,805 6,810 4,614 6,112 5,395 6,340
Book Value Per Share 2 15.50 18.70 19.80 17.30 17.30 17.80 19.00 20.80
Cash Flow per Share 2 -0.8800 0.8200 -0.6000 -1.270 0.8700 1.400 2.130 3.120
Capex 1 172 64.4 136 214 124 150 159 168
Capex / Sales 19.61% 4.31% 7.68% 10.29% 4.97% 5.31% 4.95% 4.64%
Announcement Date 2/11/20 2/16/21 2/22/22 2/21/23 2/21/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
53.34 USD
Average target price
86.59 USD
Spread / Average Target
+62.34%
Consensus
  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. Financials Exact Sciences Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW